FIG. 5.

PKCδ interacts with the TP53 promoter via Btf in cells. (A) MOLT-4 cells were left untreated or treated with ADR for 8 h. ChIP assays were performed using primer sequences containing CPE-TP53 (CPE) or other control regions of the TP53 promoter (CR) as a negative control. PCR was performed with immunoprecipitated chromatin fragments using anti-PKCδ, anti-Btf, or anti-IgG. The inputs represent PCR amplification of total chromatin before immunoprecipitation. (B) MOLT-4 cells were treated as described above. Re-ChIP assays were performed with the use of anti-PKCδ, and the eluted samples were then immunoprecipitated with anti-Btf or anti-IgG. Precipitated chromatin was analyzed by PCR using primer sequences containing the CPE-TP53 region. (C) MOLT-4 cells were treated as described above. Re-ChIP assays were performed by using anti-Btf for the first immunoprecipitation and anti-PKCδ for the second immunoprecipitation. (D) MOLT-4 cells were pretreated with or without rottlerin followed by treatment with ADR for 8 h. ChIP assays were performed by using anti-PKCδ or anti-Btf. Immunoprecipitated chromatin was analyzed by PCR using primer sequences containing CPE-TP53.